A Minimally Invasive Trial for Atrial Fibrillation Patients
The purpose of the CONVERGE clinical trial is to establish a safe, effective and minimally invasive surgery for atrial fibrillation (AFib).
If you have been diagnosed with atrial fibrillation, you may qualify for the Convergent Procedure, a "hybrid" approach that combines two AFib treatments into one therapy.
During this clinical trial, your medical care will be provided by board-certified doctors and hospitals that specialize in AFib research. You may also receive compensation for participating in this clinical trial.Start Patient Screener 60-second survey
The Convergent Procedure combines two therapies for atrial fibrillation into a single procedure that is typically performed in an electrophysiology lab.
Which Patients May Qualify?
You may be eligible for this AFib study if:
- 18-80 You are between 18 and 80 years of age
- You experience persistent Atrial Fibrillation
- Your heart medications are not working
CONVERGE is a clinical trial that is now enrolling patients that experience persistent AFib with symptoms including fatigue, shortness of breath and chest pain.